AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00143468 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mechanical ventilation
Description: measurement of specific lung elastance during mechanical ventilation
Study NCT04156399 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: All subjects will receive a standardized 18 needle acupuncture protocol.
Study NCT00687245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esomeprazole magnesium
Description: capsules, oral, qd, one day
Study NCT03163706 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Modified Stroop effect
Description: to assess whether attention deficits and executive functions in patients with schizophrenia are general (semantic and response conflict) or specific (semantic or response conflict).
Study NCT03163706 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Stroop effect
Description: to assess whether attention deficits and executive functions in patients with schizophrenia are general (semantic and response conflict) or specific (semantic or response conflict).
Study NCT04531306 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio® Tape
Description: Fascial taping technique for myofascial trigger points on the iliotibial band
Study NCT04531306 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kinesio® Tape
Description: Fascial taping technique for myofascial trigger points on the iliotibial band
Study NCT01339299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant luteinizing hormone (r-LH)
Description: administration of r-LH 150 IU/day subcutaneously , from S1 to r-hCG administration day (treatment day 10 to 14)
Study NCT01339299 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant human chorionic gonadotropin (r-hCG)
Description: administration of r-hCG 25 IU/day subcutaneously , from S1 to r-hCG administration day (treatment day 10 to 14)
Study NCT02414126 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Effect of CPAP on respiratory work and cardiac function indices during wakefulness
Description: Comparison of three periods of 3 hours~1. st period: Spontaneous breathing for 10 minutes~2. nd period: CPAP for 10 minutes~3. rd period: Spontaneous breathing for 10 minutes to check the return to baseline.~After each period, the following parameters will be recorded during 5 minutes:~* oesogastric pressures~* air flow~* gas exchange~* right and left cardiac function~Patients > 6 years old will assess their dyspnea on a visual analogue scale
Study NCT02414126 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Study NCT03624387 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Painting Sessions
Description: During the GIA painting session, each participant will be given a white canvas, four brushes and four different colors of painting.Their only instruction will be to cover the white color of the canvas. At the end of each session, the performance of the participants will be evaluated based on their neuropsychological conditions before and after Geriatric Inclusive Art session.
Study NCT02197442 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Study NCT02197442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Study NCT02946489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CI-581a
Description: CI-581a will be administered in wk2 and potentially in wk 3 or 4.
Study NCT01950156 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HLA-A*2402restricted URLC10, CDCA1, and KIF20A peptides with adjuvant
Description: Open Label, Non-Randomized, Safety/Efficacy study: patients will be vaccinated subcutaneously once a week with HLA-A\*2402restricted URLC10, CDCA1, and KIF20A peptides with adjuvant.
Study NCT00073008 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: GW572016 (lapatinib)
Description: tyrosine kinase inhibitor
Study NCT02155322 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon Alfa-2b
Description: 6 μg/kg, weekly dosing, subcutaneous administration, Induction Phase - first 8 weeks
Study NCT02155322 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon Alfa-2b
Description: 3 μg/kg SC once weekly for a 42-week maintenance phase (for a total treatment of up to approximately 1 year)
Study NCT01905592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: niraparib
Description: 300 mg (3x100 mg capsules) once daily until progression or unacceptable toxicity develops
Study NCT01905592 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Physician's choice
Description: Choice of 4 standard of care metastatic breast cancer chemotherapies, until progression or unacceptable toxicity develops
Study NCT00621517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: Partipants will receive 150 mg bupropion per night
Study NCT00621517 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule nightly for six weeks
Study NCT04564105 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: simulation education
Description: Intubation protocol will be trained by simulation exercise.
Study NCT03395847 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT04475770 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Real Sustained Natural Apophyseal Glides (SNAGS)
Description: Manual therapists use treatment modalities that include passive techniques such as mobilization and manipulation. Mobilization with movement (MWM) developed by Mulligan involves applying a sustained transverse glide to the spinous process of a vertebra while actively or passively performing. These techniques have gained the name Sustained Natural Apophyseal Glides (SNAGS) as it is maintained at the pain-free range and follows the plane of the apophyseal joints under treatment.
Study NCT04475770 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Sustained Natural Apophyseal Glides (SNAGS)
Description: The participants in the Sham SNAGs group will be positioned same as the SNAG group. Mulligan belt will be used, which included the patient's waist and physiotherapist's hip. The physiotherapist will place the hypothenar region of his hand on the spinous processes of the symptomatic lumbar spine levels and waited a few seconds without no glide will be performed. Sham SNAGs practice consisted of 3 sets of 6 repetitions and a 60-second rest period was given between the sets.
Study NCT02800395 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Malnutrition screening and perioperative nutritional support
Description: * Multidisciplinary training sessions for malnutrition and malnutrition risk screening, postoperative nutritional procedures according to the ESPEN Guidelines~* Preoperative Geriatric evaluation : eligibility criteria, nutritional status, previous history, comorbidities, clinical examination, activities of daily living (ADL) and Instrumental activities of daily living (IADL)~* Implementation of an adapted nutritional support based on ESPEN Guidelines
Study NCT01303614 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine-Prilocaine cream
Description: Implementation of 3 cm of lidocaine-prilocaine in the endocervical canal, 10 minutes before the intervention with a syringe without needle 5ml. Application, with a swab of the anesthetic cream ectocervix level.
Study NCT01303614 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 3 cm of gel application for the transmission of ultrasound into the endocervical canal 10 minutes before surgery, with a 5 ml syringe without needle. Application, with a swab in gel ectocervix.
Study NCT02651493 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: photographs
Description: computer based program to analyze photographs (computer-aided diagnosis (CAD) software)
Study NCT01260961 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The volunteers will start on the 200 mg daily of the placebo and will not increase their dose during the study.
Study NCT01260961 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Docosahexanoic Acid
Description: The volunteers will start on the 200 mg daily of the DHA capsule and will not increase their dose during the study.
Study NCT02614508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buparlisib
Description: Given PO
Study NCT02614508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO
Study NCT02614508 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Given IV
Study NCT00731731 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Undergo radiotherapy
Study NCT00731731 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cognitive Assessment
Description: Ancillary studies
Study NCT00731731 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00731731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO
Study NCT00731731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Given PO
Study NCT02417961 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Benralizumab
Description: Benralizumab administered subcutaneously every 4 weeks
Study NCT01330199 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic Sampling
Description: Blood plasma, Rectal, Cervical, and Vaginal Tissues and Secretions
Study NCT02324699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Study NCT02324699 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02697838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib (850 mg qd p.o.) until disease progression or intolerable toxicity or refused by the patients.
Study NCT02697838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel-based chemotherapeutic regimens
Description: Paclitaxel-based chemotherapeutic regimens including:~1. The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.~2. The PF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.~3. Paclitaxel 80mg/m2 d1，d8，d15，repeating the cycle every 28 days~4. other paclitaxel-based regimens
Study NCT02874105 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group C: physiotherapy protocol with Conventional physiotherapy.
Study NCT02874105 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group S: physiotherapy protocol with Dynamic Humeral Centering.
Study NCT02185547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoloft
Description: Sertraline treatment 25 mg
Study NCT02185547 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ICBT
Description: Internet behavioral cognitive therapy only
Study NCT02185547 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ICBT
Description: Internet behavioral cognitive therapy only
Study NCT01663558 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: imiquimod
Study NCT01663558 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ablative
Study NCT04467346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ped-TMZ
Description: Ped-TMZ will be administered using the provided dosing oral syringes and followed by a glass of 240 ml of water (for mouth rinsing) in sitting position and under fasting condition for at least 8 hours before dosing
Study NCT04467346 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ped-TMZ
Description: Ped-TMZ will be administered using the provided dosing oral syringes and followed by a glass of 240 ml of water (for mouth rinsing) in sitting position and under fasting condition for at least 8 hours before dosing
Study NCT03132662 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3
Description: 3 gr/day of Omega-3
Study NCT03132662 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Very Low Calorie Diet
Description: 4 servings/day Optifast
Study NCT03616964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally.
Study NCT03616964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally
Study NCT03616964 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT01097499 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OsseoPulse device (Light emitting diode technology)
Description: Patients in this group will be given the LED device and will be instructed on how and when to use it. They will receive LED treatment to the surgical site preoperatively by the surgeon for 20 minutes. Then, patients in this group will apply LED at home to the surgical site postoperatively at the day of surgery and for the following 9 postoperative days.
Study NCT01106365 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: H-coil (Repetitive deep transcranial magnetic stimulation)
Description: Repetitive deep transcranial magnetic stimulation of prefrontal cortex or motor cortex or sham stimulation
Study NCT01106365 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: H-coil (Repetitive deep transcranial magnetic stimulation)
Description: Repetitive deep transcranial magnetic stimulation of prefrontal cortex or motor cortex or sham stimulation
Study NCT01106365 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: H-coil (Repetitive deep transcranial magnetic stimulation)
Description: Repetitive deep transcranial magnetic stimulation of prefrontal cortex or motor cortex or sham stimulation
Study NCT04519593 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic myomectomy with prior temporary uterine blood supply occlusion
Description: Visualization and temporary bilateral clipping of uterine/internal iliac arteries and suspensory ligaments of ovaries.
Study NCT04519593 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional laparoscopic myomectomy
Description: Laparoscopic myomectomy without prior temporary uterine blood supply occlusion
Study NCT01350232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Subjects will receive fludarabine at a dose of 30 mg/m2 daily for 4 days as part of the preparative regimen
Study NCT01350232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Subjects will receive cytarabine at a dose of 2 g/m2 daily for 4 days, approximately 4 hours after the fludarabine
Study NCT01350232 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cellular Infusions
Description: Subjects will receive the cellular product in 2 steps. The first is a lymphocyte infusion of 2 X 10e8 lymphocytes/kg on the day they receive total body irradiation. The second is a CD34 enriched stem cell product approximately 48 hours after the cyclophosphamide.~The CliniMACS® Plus Instrument will be used for the selection of human CD34+ hematopoietic stem and progenitor cells in human allogeneic hematopoietic stem cell transplantation.
Study NCT01350232 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: All subjects will receive 200cGy TBI in a single fraction on the AM they receive the lymphocyte infusion
Study NCT01350232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: All subjects will receive cyclophosphamide at a dose of 60 mg/kg at approximately 72 and 96 hours after the lymphocyte infusion
Study NCT01350232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Subjects will receive bortezomib 1.3 mg/kg on Day 1,4,8, and 11 of a 21 day cycle. This will be repeated for 2 cycles.
Study NCT01350232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Subjects will receive rituximab 375 mg/m2 on day 1 and day 8 of a 21 day cycle, on days they will also be receiving rituximab. This will be repeated for 2 cycles.
Study NCT01350232 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Plasmapheresis
Description: Subjects who continue to have detectable anti-donor antibody will receive plasmapheresis to reduce the antibody further
Study NCT02022111 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient Education and Behavioral Activation
Description: To stimulate and motivate sustained, effective self-care, patient education materials and behavioral activation techniques that are adapted for the Indian population will be used by care coordinators. Behavioral activation strategies are brief, structured psychological interventions that are based on extensive theoretical and clinical literature, can be delivered by non-specialist providers, can be combined with antidepressant medications, and emphasize reinforcing behaviors to produce improvements in thoughts, mood, and quality of life.
Study NCT02022111 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supporting Self-Care (care coordinators)
Description: Care coordinators will: (a) meet with intervention arm patients and collaboratively set treatment goals; (b) provide verbal education regarding diabetes and depression self-care ;(c) will use motivational interviewing and self-efficacy enhancement strategies to promote monitoring of depressive symptoms, glucose, BP; (d) will proactively follow-up to externally monitor depression symptoms and CVD indicators; (e) will enter updated patient indicators into decision-support electronic health record and utilize software outputs to prioritize patients for review; (g) will convene case review meetings with supervising physicians; and (h) will communicate physician-recommended treatment changes to patients and their routine providers.
Study NCT02022111 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychiatrist and Diabetologist Reviews
Description: Senior psychiatrist and endocrinologist/diabetologist will be involved in weekly offline case review meetings with care coordinators. Case review meetings will be structured: the decision-support electronic health record will help prioritize cases that are new (within 3 weeks of randomization); have moderate/severe depression symptoms (based on Patient Health Questionnaire (PHQ)-9) ≥6 weeks after most recent treatment changes, or continued poor HbA1c, home glucose, BP, or LDL-c control in past 4 weeks; or have not been reviewed for 3 months. Based on patient indicators and current therapies, physicians will recommend treatment changes (initiation, increases, or simplification of medication regimens) which will be communicated by care coordinators to patients and their usual care providers.
Study NCT02022111 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Decision-support Electronic Health Record System
Description: The decision-support electronic health record will store patient indicators entered by the Nurse Case Managers (NCM) and provide diabetes and depression care prompts based on an evidence-based treatment algorithm developed from recommended guidelines for control of diabetes and depression, Indian formularies, and TeamCare investigators. The decision-supported electronic health record (DS-EHR) will prioritize patients (new; poorly-controlled; or well-controlled but not reviewed ≥3 months) for case review meetings and promote accountability (physicians must justify rejecting electronic care prompts).
Study NCT02022111 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Participants randomized to the control arm will receive the existing standard care and treatment for their diabetes that is provided routinely at each Clinic Site and their care provider will be notified regarding their depressive symptoms. The physicians treating the control arm will also be provided with trainings regarding identification and care for people with depression. The control participants will have no contact with care coordinators and will only be contacted at 6-monthly intervals for assessment by the blinded outcomes assessor.
Study NCT03189147 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biceps Tenodesis
Description: Surgical procedure that is usually performed for the treatment of labral lesions in patients undergoing arthroscopic rotator cuff repair
Study NCT03189147 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Debridement
Description: Surgical procedure that is usually performed for the treatment of labral lesions in patients undergoing arthroscopic rotator cuff repair
Study NCT02813083 — intervention group
Intervention type: OTHER
Intervention: No intervention (observational)
Description: No intervention (observational)
Study NCT02515006 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Homeopathy Medicine
Description: Homeopathy, or homeopathic medicine, is a holistic system of treatment. Individualized homeopathy remedy was based on the most characteristic and clear mental symptoms. Secondly, general symptoms were taken into account.C-potencies were provided and manufactured according to the Homeopathic Pharmacopoeia and Hahnemann's methodology. Each individualized homeopathic remedy were be prescribed in C-potencies